Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 17/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10205264 | 0.92 | CXCR2 (0.84) | CXCR2 | |
| SCHEMBL489582 | 0.90 | CXCR2 (0.84) | CXCR2LMNAMAPTMAPK1NPSR1 | |
| SCHEMBL12100957 | 0.90 | CXCR2 (0.66) | CXCR2LMNAPGRMAPTMAPK1 | |
| SCHEMBL489483 | 0.86 | CXCR2 (0.71) | CXCR2PGR | |
| SCHEMBL489741 | 0.85 | CXCR2 (0.73) | CXCR2 | |
| SCHEMBL490293 | 0.85 | CXCR2 (0.64) | CXCR2LMNA | |
| SCHEMBL489525 | 0.84 | CXCR2 (0.86) | CXCR2 | |
| SCHEMBL12096404 | 0.84 | CXCR2 (0.86) | CXCR2 | |
| SCHEMBL489981 | 0.82 | CXCR2 (0.85) | CXCR2 | |
| SCHEMBL489450 | 0.82 | CXCR2 (1.00) | CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1527051-B1 | PYRIMIDYL SULPHONE AMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2012-09-12 | — | — | EP | disclosed |
| US-8106063-B2 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2012-01-31 | — | — | US | disclosed |
| US-20100063079-A1 | Pyrimidyl Sulphone Amide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2010-03-11 | — | — | US | disclosed |
| US-7582644-B2 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2009-09-01 | — | — | US | disclosed |
| US-20060025432-A1 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063079-A1 | Pyrimidyl Sulphone Amide Derivatives as Chemokine Receptor Modulators | ACKR3, GPR17, CCL11 | CXCR2 38/4885LMNA 4818/4885PGR 386/4885 |
| US-20060025432-A1 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ACKR3, GPR17, CCL11 | CXCR2 38/4885LMNA 4818/4885PGR 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.